Insilico Medicine Completes First-in-Patient Dosing of ISM3412, the Novel MAT2A Inhibitor for the Treatment of Locally Advanced/Metastatic Solid Tumors
en-GBde-DEes-ESfr-FR

Insilico Medicine Completes First-in-Patient Dosing of ISM3412, the Novel MAT2A Inhibitor for the Treatment of Locally Advanced/Metastatic Solid Tumors

26.06.2025 Insilico Medicine

Bitte loggen Sie sich ein oder registrieren Sie sich, um diesen Artikel zu lesen.


Login
Register
26.06.2025 Insilico Medicine
Regions: Asia, Hong Kong
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...

  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement